HK1040490A1 - 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法 - Google Patents

通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法

Info

Publication number
HK1040490A1
HK1040490A1 HK02101917.6A HK02101917A HK1040490A1 HK 1040490 A1 HK1040490 A1 HK 1040490A1 HK 02101917 A HK02101917 A HK 02101917A HK 1040490 A1 HK1040490 A1 HK 1040490A1
Authority
HK
Hong Kong
Prior art keywords
alzheimer
onset
disease
risk
treating
Prior art date
Application number
HK02101917.6A
Other languages
English (en)
Inventor
Wolozin Benjamin
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of HK1040490A1 publication Critical patent/HK1040490A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
HK02101917.6A 1998-11-13 2002-03-12 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法 HK1040490A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/190,439 US6472421B1 (en) 1998-11-13 1998-11-13 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
PCT/US1999/026979 WO2000028981A2 (en) 1998-11-13 1999-11-15 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor

Publications (1)

Publication Number Publication Date
HK1040490A1 true HK1040490A1 (zh) 2002-06-14

Family

ID=22701366

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101917.6A HK1040490A1 (zh) 1998-11-13 2002-03-12 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法

Country Status (9)

Country Link
US (1) US6472421B1 (zh)
EP (1) EP1131060A2 (zh)
JP (1) JP2002529500A (zh)
AU (1) AU771254B2 (zh)
BR (1) BR9915267A (zh)
CA (1) CA2350420A1 (zh)
HK (1) HK1040490A1 (zh)
NO (1) NO20012317L (zh)
WO (1) WO2000028981A2 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20020188012A1 (en) * 1998-01-28 2002-12-12 Bisgaier Charles Larry Method for treating Alzheimer's disease
EP1225880A2 (en) * 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
EP1366061A4 (en) * 2001-02-05 2006-04-26 Andrx Corp METHOD FOR TREATING BETA AMYLOID PRECURSOR ILLNESSES
EP1370210A4 (en) * 2001-02-07 2004-08-18 Mclean Hospital Corp CHOLESTERINE-REDUCING AGENTS AS TREATMENT AGAINST PSYCHIC AND COGNITIVE DISORDERS
AU2002252664A1 (en) * 2001-04-13 2002-10-28 First Genetic Trust Methods and systems for managing informed consent processes
AU2002322284A1 (en) * 2001-06-25 2003-01-08 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US20050107461A1 (en) * 2002-03-12 2005-05-19 Tian-Quan Cai Drug combination therapy
AU2003234089A1 (en) * 2002-04-12 2003-10-27 Henry Ford Health System Treatment of neural injury and neurodegenerative disease with statins
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
JP2007527387A (ja) 2003-07-03 2007-09-27 リピッド サイエンシーズ，インコーポレイテッド 脂質含量の低下したｈｄｌの粒子誘導体を製造するための方法及び装置
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
AU2004305293A1 (en) * 2003-12-23 2005-07-07 Temrel Limited Process for producing pellets for pharmaceutical compositions
US20070161700A1 (en) * 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
EP1731147A4 (en) * 2004-03-31 2010-06-30 Kowa Co EXTERNAL PREPARATION
JP2009517186A (ja) * 2005-11-29 2009-04-30 チルドレンズ ホスピタル メディカル センター 薬物選択及び投薬の最適化及び個別化
TWI432195B (zh) * 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
ES2330184B1 (es) * 2008-06-03 2010-07-05 Neuron Biopharma, S.A. Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
US11027052B2 (en) 2017-11-22 2021-06-08 HDL Therapuetics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
JP2021509894A (ja) 2017-12-28 2021-04-08 エイチディーエル セラピューティクス インコーポレイテッドＨｄｌ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ヒト血漿から抽出されたｐｒｅ−β高密度リポタンパク質を保存および投与するための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
AU679675B2 (en) 1992-05-11 1997-07-10 Bayer Corporation Methods for detecting beta amyloid precursor protein processing enzymes
AU7397094A (en) 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US6537987B1 (en) 1996-06-20 2003-03-25 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
US5734054A (en) 1996-11-05 1998-03-31 Pharmacopeia, Inc. Hydroxy-amino acid amides
DE19716120A1 (de) 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
ES2257824T3 (es) 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein

Also Published As

Publication number Publication date
NO20012317D0 (no) 2001-05-10
AU771254B2 (en) 2004-03-18
CA2350420A1 (en) 2000-05-25
NO20012317L (no) 2001-07-06
JP2002529500A (ja) 2002-09-10
EP1131060A2 (en) 2001-09-12
BR9915267A (pt) 2001-12-04
AU1624100A (en) 2000-06-05
WO2000028981A2 (en) 2000-05-25
US6472421B1 (en) 2002-10-29
WO2000028981A3 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
HK1040490A1 (zh) 通過使用hmg coa還原酶抑制劑治療、預防和減輕阿爾茨海默氏病發病危險性的方法
AU1407399A (en) Treatment for alzheimer's disease
IL142906A0 (en) Methods and compositions for treating or preventing peripheral neuropathies
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
IL143921A0 (en) Compositions for the treatment and prevention of tumors and tumor-related disorders
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
ZA9810788B (en) Method and composition for the treatment and prevention of hyperuricemia
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU3113500A (en) Compositions for treating alzheimer's disease and other amyloidoses
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
IL136110A0 (en) Methods and compositions for the treatment of psoriasis
EP1109548A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING BONE DISEASES USING TOCOTRIENOLE
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer's disease.
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
NO996206D0 (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU1405899A (en) Treatment for alzheimer's disease
NZ518822A (en) Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
AU4480999A (en) Use of selenium compounds for preventing and treating Alzheimer disease
AU2002318888A1 (en) Metal Chelators for use in the treatment of Alzheimer's Disease
AUPR227000A0 (en) Agents for the treatment of alzheimer's disease and screening and methods for the same
AU2003287513A1 (en) INHIBITORS OF Beta-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT
HK1039574A1 (zh) 治療帕金森氏病、adhd和微腺瘤的藥物試劑